Rein Therapeutics Inc.

NASDAQ: RNTX · Real-Time Price · USD
1.14
-0.02 (-1.30%)
At close: Aug 15, 2025, 12:36 PM

Rein Therapeutics Income Statement

Financials in USD. Fiscal year is undefined.
Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
Revenue
n/a n/a n/a n/a
Cost of Revenue
n/a n/a n/a n/a
Gross Profit
n/a n/a n/a n/a
Operating Income
-65.11M -16.28K -27.65K -26.61K
Interest Income
400K n/a n/a n/a
Pretax Income
-64.31M -15.73K -27.33K -26.16K
Net Income
-62.88M -15.73K -27.33K -26.16K
Selling & General & Admin
13.86K 11.36K 9.68K 9.6K
Research & Development
14.25K 3.99K 17.97K 17.01K
Other Expenses
n/a 928.00 n/a n/a
Operating Expenses
65.11K 16.28K 27.65K 26.61K
Interest Expense
n/a n/a n/a n/a
Selling & Marketing Expenses
-13.85M n/a n/a n/a
Cost & Expenses
65.11K 16.28K 27.65K 26.61K
Income Tax Expense
-1.54M n/a n/a n/a
Shares Outstanding (Basic)
17.94K 4.6K 4.54K 4.44K
Shares Outstanding (Diluted)
17.94K 4.6K 4.54K 4.44K
EPS (Basic)
-3.51 -3.42 -6.02 -5.89
EPS (Diluted)
-3.51 -3.42 -6.02 -5.89
EBITDA
-28.05M -15.23K -27.48K -26.48K
EBIT
-28.11M -15.35K -27.65K -26.61K
Depreciation & Amortization
63K 119.00 169.00 121.00